Founded in 2015 and headquartered in California, TearClear is a pharmaceutical company dedicated to enhancing patient safety and compliance in ocular surface medication delivery. The company's core mission is to transform trusted drugs into best-in-class therapies for chronic eye diseases. TearClear's innovative platform captures preservatives before they reach the ocular surface, significantly improving patient outcomes. Their primary market focus includes treatments for glaucoma and other ocular surface diseases.
TearClear has garnered attention for its pioneering approach and has attracted notable investors and industry experts. The company's lead candidates in glaucoma treatment are paving the way for future indications across multiple programs. TearClear's impact is evident in its commitment to advancing ophthalmic care, setting new standards for medication delivery, and improving the quality of life for patients with chronic eye conditions.
